Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25090079 | 1.00 | TACR1 (0.45) | TACR1KMT2AMEN1MAPTCYP1A2 | |
| SCHEMBL25089778 | 0.91 | TACR1 (0.42) | TACR1KMT2AMEN1MAPTCYP1A2 | |
| SCHEMBL30200812 | 0.91 | TACR1 (0.42) | TACR1KMT2AMEN1MAPTCYP1A2 | |
| SCHEMBL30201367 | 0.89 | TACR1 (0.41) | TACR1KMT2AMEN1OPRK1OPRM1 | |
| SCHEMBL25090266 | 0.89 | TACR1 (0.41) | TACR1KMT2AMEN1OPRK1OPRM1 | |
| SCHEMBL29328339 | 0.88 | TACR1 (0.45) | TACR1KMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL30202124 | 0.88 | TACR1 (0.45) | TACR1KMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL25090446 | 0.86 | MEN1 (0.46) | TACR1KMT2AMEN1MAPTCYP1A2 | |
| SCHEMBL30201121 | 0.86 | MEN1 (0.46) | TACR1KMT2AMEN1MAPTCYP1A2 | |
| SCHEMBL25090284 | 0.85 | TACR1 (0.43) | TACR1KMT2AMEN1MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2023028056-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | CACNA1E, TRPV1, SCN3A | TACR1 174/4885KMT2A 882/4885MEN1 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.